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Atrial Fibrillation and Outcomes in Heart Failure With Preserved
Versus Reduced Left Ventricular Ejection Fraction
David D. McManus, MD, ScM; Grace Hsu, MPH; Sue Hee Sung, MPH; Jane S. Saczynski, PhD; David H. Smith, PharmD, DrPH, MPH;
David J. Magid, MD, MPH; Jerry H. Gurwitz, MD; Robert J. Goldberg, PhD; Alan S. Go, MD; for the Cardiovascular Research
Network PRESERVE Study
Background-—Atrial ﬁbrillation (AF) and heart failure (HF) are 2 of the most common cardiovascular conditions nationally and AF
frequently complicates HF. We examined how AF has impacts on adverse outcomes in HF-PEF versus HF-REF within a large,
contemporary cohort.
Methods and Results-—We identiﬁed all adults diagnosed with HF-PEF or HF-REF based on hospital discharge and ambulatory visit
diagnoses and relevant imaging results for 2005–2008 from 4 health plans in the Cardiovascular Research Network. Data on
demographic features, diagnoses, procedures, outpatient pharmacy use, and laboratory results were ascertained from health plan
databases. Hospitalizations for HF, stroke, and any reason were identiﬁed from hospital discharge and billing claims databases. Deaths
were ascertained from health plan and state death ﬁles. Among 23 644 patients with HF, 11 429 (48.3%) had documented AF (9081
preexisting, 2348 incident). Compared with patients who did not have AF, patients with AF had higher adjusted rates of ischemic stroke
(hazard ratio [HR] 2.47 for incidentAF;HR1.57 for preexistingAF), hospitalization for HF (HR2.00 for incident AF;HR1.22 for preexisting
AF), all-cause hospitalization (HR 1.45 for incident AF; HR 1.15 for preexisting AF), and death (incident AF HR 1.67; preexisting AF HR
1.13). The associations of AF with these outcomes were similar for HF-PEF and HF-REF, with the exception of ischemic stroke.
Conclusions-—AF is a potent risk factor for adverse outcomes in patients with HF-PEF or HF-REF. Effective interventions are
needed to improve the prognosis of these high-risk patients. ( J Am Heart Assoc. 2013;2:e005694 doi: 10.1161/
JAHA.112.005694)
Key Words: atrial ﬁbrillation • heart failure • hospitalization • mortality • systolic function
H eart failure (HF) and atrial ﬁbrillation (AF) represent 2worsening epidemics nationally and internationally.1–3
AF remains the most common, clinically relevant arrhythmia
in adults and is independently associated with a 4- to 5-fold
higher risk of ischemic stroke, as well as poorer quality of life,
higher hospitalization rates, and excess mortality.4–6 AF
frequently complicates HF, affecting approximately one third
of all adults with HF.7 However, the epidemiology of HF has
been changing, with an increasing proportion of patients
being diagnosed with HF and preserved left ventricular
ejection fraction (HF-PEF).8 Limited data exist on contempo-
rary incidence rates and outcomes associated with AF in the
setting of HF-PEF compared with HF and reduced ejection
fraction (HF-REF).9
Within a large, multicenter cohort of adults with HF, we
examined the association of preexisting versus incident AF




The source population included members from 4 partic-
ipating health plans within the National Heart, Lung, and
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Blood Institute–sponsored Cardiovascular Research Net-
work (CVRN).10 Sites included Kaiser Permanente North-
ern California, Kaiser Permanente Colorado, Kaiser
Permanente Northwest, and Fallon Community Health
Plan. The sites were identiﬁed on the basis of providing
care to an ethnically and socioeconomically diverse
population across varying clinical practice settings and
geographically diverse areas. Each site also had a Virtual
Data Warehouse (VDW),10 which served as the primary
data source for identifying and characterizing study
subjects. The CVRN VDW is a distributed standardized
data resource composed of linked demographic, phar-
macy, laboratory test results, and health care utilization
(outpatient visits as well as health plan and non–health
plan hospitalizations with diagnoses and procedures) data
for health plan members receiving care within participat-
ing CVRN sites.10,11
Institutional review boards at participating sites approved
the study, and waiver of consent was obtained due to the
nature of the study.
Study Sample
We identiﬁed all individuals aged ≥21 years with diagnosed
HF between January 1, 2005, through December 31, 2008,
based on either ≥1 hospitalization with a primary discharge
diagnosis of HF and/or ≥3 ambulatory visits coded for HF
with ≥1 of the ambulatory diagnoses from a cardiologist to
enhance diagnostic speciﬁcity. The following International
Classiﬁcation of Diseases, Ninth Edition (ICD-9) codes were
used to identify potential HF cases: 398.91, 402.01,
402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23,
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42,
428.43, and 428.9. When compared against medical record
abstraction and use of the Framingham Heart Study clinical
criteria, use of the primary discharge diagnosis of HF based
on these codes showed a positive predictive value of
>95%.12–14 We determined the level of left ventricular
systolic function closest to the qualifying HF diagnosis,
based on clinically obtained echocardiograms and other
relevant imaging modalities. We classiﬁed patients into
categories of preserved and reduced left ventricular ejection
fraction. We deﬁned PEF as left ventricular ejection fraction
≥50% and/or a physician’s qualitative assessment of pre-
served or normal systolic function.15 REF was deﬁned as
left ventricular ejection fraction ≤40% and/or a physician’s
qualitative assessment of moderate, moderate-to-severe, or
severe systolic dysfunction. To limit misclassiﬁcation, we
excluded participants with ejection fraction >40% and <50%
and/or a physician’s qualitative assessment of mild systolic
dysfunction.
Deﬁnition of AF
We ascertained AF based on ≥1 primary hospital discharge
and/or ≥2 ambulatory diagnoses of AF (ICD-9 code 427.31)
or atrial ﬂutter (ICD-9 code 427.32) from each site’s VDW.4
We deﬁned preexisting AF as AF documented any time during
the 5 years before cohort entry, and incident AF as AF
occurring anytime during follow-up among those patients with
HF without AF at baseline.
Follow-up and Outcomes
Follow-up occurred through December 31, 2008, which was
the latest date on which complete data on death were
available at the time of analysis. Subjects were censored if
they disenrolled from the health plan or reached the end of
study follow-up. Hospitalizations for HF were identiﬁed from
each site’s VDW based on a primary discharge diagnosis for
HF using the same inclusion criteria ICD-9 codes. Ischemic
strokes were identiﬁed from hospital discharge and billing
claims databases using previously validated ICD-9 codes.16
Occurrence of death was identiﬁed using data from member
proxy report, state death certiﬁcate registries, and Social
Security Administration ﬁles as available at each site. These
approaches have yielded >97% vital status information in our
prior studies.13,17
Covariates
We ascertained information on coexisting illnesses based on
diagnoses or procedures using relevant ICD-9 codes, labora-
tory results, or ﬁlled outpatient prescriptions from health plan
hospitalization discharge, ambulatory visit, laboratory, and
pharmacy databases, as well as from site-speciﬁc diabetes
mellitus and cancer registries.18 We deﬁned prevalent HF as
any hospitalization or ambulatory HF diagnosis before the
index date. We collected baseline and follow-up data on
diagnoses of coronary artery disease, acute myocardial
infarction, coronary artery revascularization, stroke and
transient ischemic attack, peripheral artery disease, diabetes,
hypertension, cancer, liver disease, valvular heart disease,
lung disease, and ventricular ﬁbrillation/tachycardia based on
previously described ICD-9 codes and Current Procedural
Terminology procedure codes.18 For the purposes of this
study, “baseline” was deﬁned by the period 5 years before the
index date for data regarding comorbidities and laboratory
values. For medication use, “baseline” was determined by any
use within 120 days before the index date and active use
within 30 days of index date.
Using each site’s VDW, we captured ambulatory measure-
ments of systolic and diastolic blood pressure, serum low-
density lipoprotein cholesterol, and blood hemoglobin level on
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or before the index date and during follow-up. We also
classiﬁed baseline and longitudinal kidney function using the
Chronic Kidney Disease Epidemiology Collaboration formula
for estimating glomerular ﬁltration rate (mL/min per 1.73 m2)
based on outpatient serum creatinine results.19 We charac-
terized longitudinal receipt of HF-related medications includ-
ing angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, b-blockers, digoxin, thiazide and loop
diuretics, nitrates, aldosterone receptor antagonists, and
statins using previously described methods.12 We also
identiﬁed receipt of cardiac resynchronization therapy (with
or without deﬁbrillator), implantable-cardioverter deﬁbrillator
placement, and pacemaker placement using ICD-9 procedure
and Current Procedural Terminology codes.10
Data Analyses
All analyses were conducted using SAS statistical software,
version 9.2 (SAS Institute). We compared baseline character-
istics by AF status (none, preexisting AF, and incident AF)
using the following methods: Kruskal–Wallis test for compar-
ing median values, ANOVA for comparing mean values, and v2
tests for comparing categorical variables. Because exclusion
of the 8639 participants with rheumatic and aortic or mitral
valve disease did not materially affect study ﬁndings, we
included these participants in the main analysis. Although we
considered a 2-sided P value <0.05 as statistically signiﬁcant,
given the large sample size, we focused only on differences
across groups that may be clinically meaningful.
We calculated rates (per 100 person-years) and associated
95% CIs for each outcome according to AF status among
patients with HF, overall and stratiﬁed by HF-PEF versus
HF-REF using a time-to-event approach. We then conducted
multivariable extended Cox regression models to examine the
association between AF status and each outcome, overall and
separately in those with HF-PEF versus HF-REF. Death was
treated as a censoring event when analyzing time to event
outcomes.
Results
Among 23 644 adults with HF, 60% had conﬁrmed HF-PEF
(mean age 74.2 years, 47.7% were women, and 76.1% were
white). Overall, 9081 (38.4%) had preexisting AF and 2348
(9.9%) had developed newly diagnosed (incident) AF during
the study period (Table 1). The frequencies of preexisting and
incident AF were 43.2% and 9.5%, respectively, in those with
HF-PEF, and 31.4% and 10.5%, respectively, in participants
with HF-REF. As expected, there was a high burden of vascular
and nonvascular morbidity at study entry in the overall cohort
(Table 1). Of note, at baseline, 58% of the overall cohort
received an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker, 63% of participants received a
b-blocker, and 26% received a calcium channel blocker
(Table 2).
AF and Death From Any Cause
Median follow-up of the overall cohort was 1.8 years
(interquartile range 0.8 to 3.1). The rate of death from any
cause in the overall cohort was 14.1 per 100 person-years
(95% CI 13.8 to 14.5). The crude rate (per 100 person-years)
of death was higher in those with incident AF compared with
those who had preexisting AF or no AF (Table 3). In the overall
cohort, after adjustment for potential confounders, compared
with those who did not have AF, incident and preexisting AF
was associated with a higher risk of death, with adjusted
hazard ratios (HRs) of 1.67 (95% CI 1.52 to 1.84) and 1.13
(95% CI 1.07 to 1.20), respectively. Similar ﬁndings were
found in those with HF-REF versus HF-PEF (Table 4). Further
adjustment for longitudinal use of medications (eg, angioten-
sin-converting enzyme inhibitors, angiotensin receptor block-
ers, aldosterone antagonists, b-blockers, calcium channel
blockers, digoxin, thiazide and loop diuretics, nitrates, statins,
other lipid-lowering therapies, anticoagulants, and antiplatelet
agents) during follow-up did not signiﬁcantly alter the
observed associations.
AF and Ischemic Stroke
The rate of ischemic stroke was 2.0 per 100 person-years
(95% CI 1.9 to 2.2) in the overall cohort. Crude rates (per 100
person-years) of ischemic stroke were 1.5, 2.5, and 3.4 for
those with no AF, preexisting AF, and incident AF, respectively
(Table 3). In the overall cohort, after adjustment for potential
confounders, compared with patients who did not have AF,
preexisting AF and incident AF were associated with a higher
risk of ischemic stroke, with HR 1.57 (95% CI 1.34 to 1.83)
and 2.47 (95% CI 1.97 to 3.09), respectively (Table 4).
Incident AF was associated with a 2-fold higher HR of
ischemic stroke in patients with HF-PEF as well as HF-REF, but
preexisting AF was associated with ischemic stroke only in
those with HF-PEF (Table 4). Additional adjustment for
longitudinal cardiovascular medication use did not materially
change the results.
AF and Hospitalization for HF
In the overall cohort, the rate of hospitalization for HF was
16.6 per 100 person-years (95% CI 16.2 to 17.0). Crude rates
(per 100 person-years) were higher in those with preexisting
AF (18.9) or with incident AF (19.6) compared with patients
who did not have AF (14.9) (Table 3). In the overall cohort,
DOI: 10.1161/JAHA.112.005694 Journal of the American Heart Association 3
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Table 1. Baseline Characteristics Among 23 644 Adults With Heart Failure and Preserved or Reduced Left Ventricular Systolic
Function Identiﬁed During 2005–2008, Overall and Stratiﬁed by AF Status
Variable Overall (N=23 644) No AF (N=12 215) Preexisting AF (N=9081) Incident AF (N=2348) P Value
Age (y), mean (SD) 74.2 (12.1) 71.6 (13.1) 77.5 (10.2) 75.4 (10.6) <0.001
Age categories, y <0.001
<45 484 (2.0) 418 (3.4) 51 (0.6) 15 (0.6)
45 to 64 4584 (19.4) 3185 (26.1) 1024 (11.3) 375 (16.0)
65 to 74 5838 (24.7) 3172 (26.0) 2042 (22.5) 624 (26.6)
≥75 12 738 (53.9) 5440 (44.5) 5964 (65.7) 1334 (56.8)
Female sex, n (%) 11 283 (47.7) 5880 (48.1) 4362 (48.0) 1041 (44.3) 0.003
Race, n (%) <0.001
White 17 985 (76.1) 8665 (70.9) 7489 (82.5) 1831 (78.0)
Black/African American 1799 (7.6) 1260 (10.3) 356 (3.9) 183 (7.8)
Asian 1194 (5.0) 681 (5.6) 406 (4.5) 107 (4.6)
Native Hawaiian/other Paciﬁc Islander 178 (0.8) 117 (1.0) 44 (0.5) 17 (0.7)
Missing 2488 (10.5) 1492 (12.2) 786 (8.7) 210 (8.9)
Clinical characteristics, n (%)
Acute myocardial infraction 3080 (13.0) 1832 (15.0) 957 (10.5) 291 (12.4) <0.001
Unstable angina 1630 (6.9) 916 (7.5) 566 (6.2) 148 (6.3) 0.001
Coronary artery bypass graft surgery 1450 (6.1) 782 (6.4) 537 (5.9) 131 (5.6) 0.17
Percutaneous coronary intervention 2346 (9.9) 1413 (11.6) 725 (8.0) 208 (8.9) <0.001
Ischemic stroke 1235 (5.2) 535 (4.4) 599 (6.6) 101 (4.3) <0.001
Cerebrovascular disease 4990 (21.1) 2419 (19.8) 2093 (23.0) 478 (20.4) <0.001
Other thromboembolic event 191 (0.8) 79 (0.6) 96 (1.1) 16 (0.7) 0.003
Ventricular tachycardia or ﬁbrillation 751 (3.2) 354 (2.9) 333 (3.7) 64 (2.7) 0.003
Mitral and/or aortic valvular disease 5928 (25.1) 2318 (19.0) 3010 (33.1) 600 (25.6) <0.001
Peripheral arterial disease 2001 (8.5) 985 (8.1) 836 (9.2) 180 (7.7) 0.004
Rheumatic heart disease 585 (2.5) 212 (1.7) 327 (3.6) 46 (2.0) <0.001
Cardiac resynchronization therapy 54 (0.2) 18 (0.1) 26 (0.3) 10 (0.4) 0.01
Implantable-cardioverter deﬁbrillator 806 (3.4) 418 (3.4) 313 (3.4) 75 (3.2) 0.83
Pacemaker 1648 (7.0) 588 (4.8) 931 (10.3) 129 (5.5) <0.001
Dyslipidemia 15 943 (67.4) 8499 (69.6) 5835 (64.3) 1609 (68.5) <0.001
Hypertension 18 735 (79.2) 9597 (78.6) 7279 (80.2) 1859 (79.2) 0.02
Diabetes mellitus 5694 (24.1) 2961 (24.2) 2163 (23.8) 570 (24.3) 0.76
Hospitalized bleed 1578 (6.7) 655 (5.4) 785 (8.6) 138 (5.9) <0.001
Diagnosed dementia 1787 (7.6) 853 (7.0) 796 (8.8) 138 (5.9) <0.001
Diagnosed depression 4439 (18.8) 2459 (20.1) 1583 (17.4) 397 (16.9) <0.001
Chronic lung disease 9904 (41.9) 4992 (40.9) 3961 (43.6) 951 (40.5) <0.001
Chronic liver disease 925 (3.9) 497 (4.1) 346 (3.8) 82 (3.5) 0.34
Mechanical fall 796 (3.4) 364 (3.0) 367 (4.0) 65 (2.8) <0.001
Systemic cancer 1780 (7.5) 894 (7.3) 736 (8.1) 150 (6.4) 0.009
Baseline laboratory characteristics, mean (SD)
eGFR, mL/min per 1.73 m2 59.6 (22.9) 61.3 (24.4) 57.7 (20.8) 58.5 (21.0) <0.001
Hemoglobin, g/L 13.1 (1.9) 13.1 (1.9) 13.1 (1.8) 13.2 (1.9) 0.007
Continued
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after adjustment for several potential confounders, compared
with patients who did not have AF, preexisting AF was
associated with a higher adjusted HR of hospitalization for HF
(HR 1.22, 95% CI 1.15 to 1.29), and incident AF was
associated with a 2-fold higher adjusted HR of hospitalization
for HF (HR 2.00, 95% CI 1.83 to 2.18), with similar results in
those with HF-PEF or HF-REF (Table 4). Further adjustment for
longitudinal medication use did not alter ﬁndings appreciably
(Table 4).
AF and Hospitalization From Any Cause
The rate of hospitalization from any cause in the overall cohort
was 68.2 per 100 person-years (95% CI 67.1 to 69.2). Crude
rates (per 100 person-years) were higher in those with
preexisting AF (75.3) or incident AF (81.0) compared with
patients who did not have AF (63.1) (Table 3). In the overall
cohort, after adjustment for potential confounders, compared
with patients who did not have AF, preexisting and incident AF
were associated with higher risk of hospitalization from any
cause, with HR of 1.15 (95% CI 1.11 to 1.19) and HR of 1.45
(1.37 to 1.54), respectively, and similar results in those with
HF-PEF or HF-REF (Table 4). Additional adjustment for
longitudinal medication use did not materially affect the
results.
Discussion
Within a multiethnic community-based cohort of >23 600
adults with HF, we demonstrate that both preexisting and
incident AF are common in patients with HF and are
associated with major adverse cardiovascular outcomes.
Newly diagnosed AF complicating HF was associated with
the highest risk for adverse complications, but the higher
Table 2. Baseline Medication Use Among 23 644 Adults With Heart Failure and Preserved or Reduced Left Ventricular Systolic
Function Identiﬁed During 2005–2008, Overall and Stratiﬁed by AF Status
Baseline Medication Use* Overall (N=23 644) No AF (N=12 215) Preexisting AF (N=9081) Incident AF (N=2348) P-Value
ACEI/ARB 13 686 (57.9) 7206 (59.0) 5099 (56.2) 1381 (58.8) <0.001
Aldosterone receptor antagonist 1963 (8.3) 997 (8.2) 770 (8.5) 196 (8.3) 0.71
b-Blocker 14 807 (62.6) 7411 (60.7) 6000 (66.1) 1396 (59.5) <0.001
Calcium channel blocker 6089 (25.8) 2911 (23.8) 2596 (28.6) 582 (24.8) <0.001
Digoxin 4115 (17.4) 1107 (9.1) 2732 (30.1) 276 (11.8) <0.001
Diuretic (loop) 11 969 (50.6) 5771 (47.2) 5018 (55.3) 1180 (50.3) <0.001
Diuretic (thiazide) 4257 (18.0) 2227 (18.2) 1565 (17.2) 465 (19.8) 0.01
Nitrate 4591 (19.4) 2532 (20.7) 1566 (17.2) 493 (21.0) <0.001
Statin 12 528 (53.0) 6758 (55.3) 4486 (49.4) 1284 (54.7) <0.001
Other lipid-lowering drug 1377 (5.8) 766 (6.3) 461 (5.1) 150 (6.4) 0.001
Antiplatelet agent 2237 (9.5) 1416 (11.6) 587 (6.5) 234 (10.0) <0.001
Anticoagulant 5555 (23.5) 751 (6.1) 4545 (50.0) 259 (11.0) <0.001
Statin 12 528 (53.0) 6758 (55.3) 4486 (49.4) 1284 (54.7) <0.001
Other lipid-lowering drug 1377 (5.8) 766 (6.3) 461 (5.1) 150 (6.4) 0.001
AF indicates atrial ﬁbrillation; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*From 120 days before index date.
Table 1. Continued
Variable Overall (N=23 644) No AF (N=12 215) Preexisting AF (N=9081) Incident AF (N=2348) P Value
Systolic blood pressure, mm Hg 130.7 (19.2) 132.1 (19.9) 128.6 (18.1) 131.9 (18.6) <0.001
Diastolic blood pressure, mm Hg 75.8 (11.3) 76.2 (11.5) 75.2 (11.0) 76.6 (10.8) <0.001
HDL, g/dL 47.7 (14.8) 47.4 (14.5) 47.9 (15.0) 48.2 (14.9) 0.03
LDL, g/dL 96.7 (33.7) 99.2 (35.1) 93.4 (31.7) 96.8 (32.5) <0.001
AF indicates atrial ﬁbrillation; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
DOI: 10.1161/JAHA.112.005694 Journal of the American Heart Association 5
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multivariable adjusted hazards of ischemic stroke, hospital-
ization for HF, hospitalization for any cause, and death
associated with AF did not materially differ between partic-
ipants with HF-PEF and those with HF-REF. These associations
persisted even after accounting for a broad spectrum of
potential confounders as well as differential longitudinal
exposure to relevant medications.
We found that nearly one third of patients with HF-REF had
preexisting AF, which is consistent with previous estimates
(15% to 35%).20–23 Although data are more limited for patients
with HF-PEF, the frequency of preexisting AF (43.2%) among
patients with HF-PEF with our study was similar to the
proportion of patients with AF in the Irbesartan in heart failure
with PRESERVEd systolic function (I-PRESERVE) study as well
as 2 studies involving 2802 (31.8%) and 6072 (41.3%)
subjects with HF conducted in 2001.24 We also noted a high
and relatively similar rate of new-onset AF complicating
HF-REF and HF-PEF, with approximately 1 in 10 participants
developing AF during a median 1.8 years of follow-up.
Incidence rates of AF observed in our study are signiﬁcantly
higher than those reported in 2 community-based investiga-
tions involving 708 and 1664 patients with HF, in which 17%
and 23% of patients with HF developed new-onset AF during
4 years of follow-up, respectively.7 The higher rate of incident
AF in our study likely relates to the higher proportion of
subjects with HF-PEF, higher prevalence of AF risk factors,
including hypertension and diabetes, and access to ambula-
tory diagnosis data, compared with other studies.
The epidemiologic similarities between AF and HF, as well
as their frequent concurrence, are explained, at least in part,
by shared underlying risk factors, including hypertension,
diabetes mellitus, chronic kidney disease, ischemic heart
disease, and valvular heart disease.25 As expected, we found
that patients with HF with AF in our cohort were more likely to
have worse kidney function, documented hypertension, and
known valvular heart disease.26 Notably, however, patients
with HF and AF were not more likely to have diabetes or
coronary artery disease than were patients without AF, which
is consistent with other studies.27,28
Absolute rates of death in our study were high and
consistent with rates seen in previous studies of patients with
AF and HF. Among 1470 individuals with HF from the
Table 3. Crude and Adjusted Rates for Ischemic Stroke, Hospitalization for Heart Failure, Hospitalization for Any Cause, Death
From Any Cause Among 23 644 Patients With Heart Failure, Overall and Stratiﬁed by AF Status







Rate per 100 Person-years,
Adjusted for Age and
Sex (95% CI)
Crude and adjusted rates to death from any cause
Overall 6394 (27.0) 45 313.7 1.9 (1.3) 14.1 (13.8 to 14.5) 14.1 (14.1 to 14.2)
No AF 2866 (19.4) 25 431.3 1.7 (1.3) 11.3 (10.9 to 11.7) 12.4 (12.4 to 12.5)
Preexisting AF 2853 (31.4) 16 710.8 1.8 (1.3) 17.1 (16.4 to 17.7) 15.2 (15.1 to 15.2)
Incident AF 675 (28.8) 3178.1 1.4 (1.1) 21.2 (19.6 to 22.8) 20.3 (20.2 to 20.4)
Crude and adjusted rates to ﬁrst hospitalization for heart failure
Overall 6273 (26.5) 37 763.3 1.5 (1.3) 16.6 (16.2 to 17.0) 16.6 (16.5 to 16.7)
No AF 3233 (22.2) 21 741.6 1.5 (1.3) 14.9 (14.4 to 15.4) 15.4 (15.3 to 15.4)
Preexisting AF 2598 (28.6) 13 766.0 1.5 (1.3) 18.9 (18.2 to 19.6) 17.7 (17.7 to 17.8)
Incident AF 442 (23.9) 2260.8 1.2 (1.1) 19.6 (17.7 to 21.4) 19.1 (19.0 to 19.2)
Crude and adjusted rates to ﬁrst hospitalization for any cause
Overall 15 744 (66.6) 23 099.1 1.0 (1.1) 68.2 (67.1 to 69.2) 68.2 (67.4 to 68.9)
No AF 8795 (60.4) 13 944.9 1.0 (1.1) 63.1 (61.8 to 64.4) 65.0 (64.3 to 65.6)
Preexisting AF 6224 (68.5) 8261.9 0.9 (1.0) 75.3 (73.5 to 77.2) 71.8 (71.0 to 72.6)
Incident AF 725 (64.7) 895.3 0.8 (0.9) 81.0 (75.1 to 86.9) 78.1 (77.2 to 79.0)
Crude and adjusted rates to ﬁrst ischemic stroke
Overall 906 (3.8) 44 531.3 1.9 (1.3) 2.0 (1.9 to 2.2) 2.0 (2.0 to 2.0)
No AF 385 (2.6) 25 079.0 1.7 (1.3) 1.5 (1.4 to 1.7) 1.6 (1.6 to 1.6)
Preexisting AF 417 (4.6) 16 402.1 1.8 (1.3) 2.5 (2.3 to 2.8) 2.3 (2.3 to 2.3)
Incident AF 104 (4.5) 3056.5 1.3 (1.1) 3.4 (2.8 to 4.1) 3.5 (3.5 to 3.5)
AF indicates atrial ﬁbrillation.
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Framingham Heart Study, incident AF was associated with a
60% higher risk for death in men and nearly 3-fold higher risk
for death in women.7 Among participants in the Candesartan
in Heart failure—Assessment of Reduction in Mortality and
morbidity (CHARM) study, crude death rates were 24% in
those with AF and HF-PEF and 37% in those with HF-REF.28 In
contrast to CHARM,28 in our study of 23 644 participants
with HF, we found that incident AF was associated with a
notably higher rate of death that was similar in those with
HF-PEF or HF-REF. The reasons for the differences between
our study and CHARM are not clear but may relate to differences
between the selected subjects with HF enrolled in the CHARM
clinical trial versus the more representative patients with HF
treated in community-based practice settings in our study.
As expected, we found that AF was associated with an
elevated risk for ischemic stroke in adults with HF. We
observed that incident AF conveyed a particularly high hazard
of ischemic stroke (2.5-fold higher adjusted rates compared
with no AF), which is consistent with previous analyses.29 Of
note, however, preexisting AF was associated with higher
adjusted hazard of ischemic stroke in those with HF-PEF but
not for those with HF-REF. Although the CHARM investigators
reported higher rates of ischemic stroke in patients with
known AF and HF-PEF compared with HF-REF (9% versus 6%,
respectively), this difference did not achieve statistical
signiﬁcance (P=0.32).28 However, the CHARM study was
underpowered to evaluate the association between prevalent
AF and ischemic stroke due to a low number of fatal or
nonfatal strokes in their cohort with AF (total n=28). The
reasons for why preexisting AF was a strong predictor of
ischemic stroke in those with HF-PEF but not HF-REF are not
clear, but patients with preexisting AF may have preferentially
experienced stroke or other AF-related complications and
death before the development of HF and therefore led to a
more selected subgroup of patients with preexisting AF and
HF in our cohort. Although we adjusted for age, the
Table 4. Association Between AF and Death From Any Cause, Hospitalization for Heart Failure, Hospitalization for Any Cause, and
Ischemic Stroke Among 24 175 Adults With Heart Failure, Overall and Stratiﬁed by Preserved and Reduced Ventricular Systolic
Function (2005–2008)





Death from any cause, adjusted* hazard ratio (95% CI)
No AF Reference Reference Reference
Preexisting AF 1.13 (1.07 to 1.20) 1.11 (1.03 to 1.20) 1.15 (1.05 to 1.26)
Incident AF 1.67 (1.52 to 1.84) 1.62 (1.42 to 1.84) 1.72 (1.48 to 1.98)
Hospitalization for heart failure, adjusted* hazard ratio (95% CI)
No AF Reference Reference Reference
Preexisting AF 1.22 (1.15 to 1.29) 1.26 (1.17 to 1.37) 1.16 (1.05 to 1.27)
Incident AF 2.00 (1.83 to 2.18) 1.96 (1.73 to 2.22) 2.04 (1.80 to 2.31)
Hospitalization for any cause, adjusted* hazard ratio (95% CI)
No AF Reference Reference Reference
Preexisting AF 1.15 (1.11 to 1.19) 1.16 (1.11 to 1.21) 1.12 (1.06 to 1.18)
Incident AF 1.45 (1.37 to 1.54) 1.43 (1.33 to 1.54) 1.49 (1.37 to 1.63)
Ischemic stroke, adjusted† hazard ratio (95% CI)
No AF Reference Reference Reference
Preexisting AF 1.57 (1.34 to 1.83) 1.91 (1.56 to 2.33) 1.07 (0.82 to 1.39)
Incident AF 2.47 (1.97 to 3.09) 2.72 (2.05 to 3.61) 2.16 (1.48 to 3.14)
AF indicates atrial ﬁbrillation; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*All models were also adjusted for age, sex, left ventricular ejection fraction (in overall models only), prevalent heart failure, acute myocardial infarction, unstable angina, coronary artery
bypass graft surgery, percutaneous coronary intervention, ischemic stroke, other thromboembolic event, ventricular ﬁbrillation or ventricular tachycardia, peripheral arterial disease,
cardiac resynchronization therapy, implantable-cardioverter deﬁbrillator, pacemaker, dyslipidemia, hypertension, diabetes mellitus, hospitalized bleeds, diagnosed dementia, diagnosed
depression, chronic lung disease, chronic liver disease, mechanical fall, systemic cancer, estimated GFR, hemoglobin, systolic blood pressure, HDL cholesterol, LDL cholesterol, race,
and site.
†Ischemic stroke outcome models were adjusted for age, sex, left ventricular ejection fraction (in overall models only), prevalent heart failure, acute myocardial infarction, unstable angina,
coronary artery bypass graft surgery, percutaneous coronary intervention, prevalent ischemic stroke, other thromboembolic event, ventricular ﬁbrillation or ventricular tachycardia,
peripheral arterial disease, cardiac resynchronization therapy, implantable cardioverter deﬁbrillator, pacemaker, dyslipidemia, hypertension, diabetes mellitus, hospitalized bleeds,
diagnosed dementia, diagnosed depression, chronic lung disease, chronic liver disease, mechanical fall, systemic cancer, estimated GFR, hemoglobin, systolic blood pressure, HDL
cholesterol, LDL cholesterol, race, and site.
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interaction between age and risk for ischemic stroke might
have modiﬁed the relation between preexisting AF and HF-PEF
in a manner distinct from HF-REF. Moreover, although we did
not observe signiﬁcant differences in the death rates of
patients with HF-PEF compared with HF-REF, it is also
possible that our ﬁndings could also be explained by the fact
that patients with HF-REF may have been more likely than
patients with HF-PEF to die before ischemic stroke develops.
Overall rates of hospitalization observed in our study
(66.6%) were higher than those reported in a study of 17 448
Medicare beneﬁciaries hospitalized for HF (44% rehospitalized
in the 6 months after discharge) during 1991–1994.30 In
contrast to the ﬁndings of a Japanese HF registry, which
included 319 patients with HF hospitalized in 2006–2007,31
we observed a signiﬁcant increase in adjusted rates of
HF-related and all-cause hospitalization among patients with
preexisting and incident AF. Our ﬁndings are consistent with
those of the CHARM substudy, which found a 4-fold higher
risk for cardiovascular-related rehospitalization in patients
with new-onset AF and HF, regardless of systolic function.28
Even after extensive adjustment for potential confounders and
longitudinal use of therapies, we found an approximately 1.5-
fold higher hazard of hospitalization associated with incident
AF. The difference in the magnitude of association between
these ﬁndings may be explained by the greater comorbid
disease burden in our community-based cohort compared
with the younger and healthier participants enrolled in the
CHARM clinical trial. This hypothesis is supported by the
overall higher rates of HF and all-cause hospitalizations in our
study relative to CHARM. Our ﬁnding that AF had a similarly
negative impact on HF-speciﬁc and all-cause hospitalizations
among patients with HF-PEF and those with HF-REF highlight
the importance of AF on the high burden and cost to patients
and the health care system.
Our study included a large socioeconomically and racially
diverse multicenter cohort recruited from multiple geographic
areas and varying clinical practice settings. Another strength
of our study is the use of a standardized data resource (CVRN
VDW) with linked demographic, health care utilization, phar-
macy, laboratory, and vital status information. Our study also
had several limitations. Our study was conducted in an
insured population, so the ﬁndings may not be fully gener-
alizable to uninsured persons or other practice settings. The
large sample size facilitated many statistically signiﬁcant
ﬁndings, but we focused on clinically meaningful effect sizes.
Information was unavailable on the type of AF (eg, paroxys-
mal, persistent, permanent), although previous studies sup-
port similar relationships between AF type and the risk of
ischemic stroke.32 We did not include information about
certain AF treatment modalities, including AF ablation, but
prior investigations have not consistently shown that AF
ablation reduces HF hospitalizations, total death rates, or the
risk of stroke.33 Because we relied on clinically obtained
assessments of left ventricular systolic function, systematic
data on structural aspects of the atria were unavailable.
However, we believe that our sample represents a “real world”
cohort of adults with clinically recognized HF managed in
typical care settings and therefore provides generalizable
results to the broader US population.
In sum, both preexisting and new-onset AF were frequent
complications of HF and increased the rates of ischemic
stroke, hospitalization for HF or any cause, and death, overall
and similarly in those with HF-PEF or HF-REF. Incident AF
consistently carried a worse prognosis for each of these
outcomes compared with preexisting AF. Our study empha-
sizes the need to develop novel prevention strategies for AF
and its associated complications in patients with HF-PEF and
HF-REF.
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